Entera Bio Ltd - Warrants (02/07/2023)
ENTXW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.54K
Close$
$0.37
30433.3% upside
Current Fair Value
30433.3% upsideUndervalued by 30433.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $60,541.00 |
|---|---|
| Enterprise Value | $-10,823,459.00 |
| Earnings per Share | $-0.25 |
| Beta | 0 |
| Outstanding Shares | 50,451,232 |
Return
| Return on Equity | 219.52% |
|---|---|
| Return on Assets | 81.88% |
| Return on Invested Capital | -18.42% |
Valuation & Multiples
| P/E Ratio | -9.23 |
|---|---|
| PEG | 2.46 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -170.52 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Entera Bio Ltd
17 employees
CEO: Adam Gridley
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challeng...